AbbVie Partners with Valkai to Integrate AI into Clinical Development

Key Facts

1AbbVie announced a new collaboration with Valkai to integrate the latter's AI platform into clinical development processes.

AbbVie announced a new collaboration with Valkai to integrate the latter's AI platform into its clinical development processes. According to Pluang, the partnership aims to utilize artificial intelligence to enhance research efficiency and accelerate the delivery of new medicines to patients.

ABBV closed at $266.28 on September 28, 2026, prior to the move to strengthen data-driven innovation. By embedding Valkai’s platform, AbbVie seeks to improve clinical insights and reduce overall drug development timelines across its operations.